Skip to main content
Equibles
FENC logo

FENC · Fennec Pharmaceuticals Inc. · Metrics

Track FENC — free

Use FENC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research FENC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.62 +0.47 (+4.63%) Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$355.93M
Shares
35.07M
Volume · Oct 27 93.19K Avg daily vol (3M) 184.23K

FENC metrics

78 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$10.62
Market cap
$355.93M

Price action

20 metrics
Price change (1W)
-1.2%
Price change (30D)
-7.3%
Price change (3M)
-0.6%
Price change (6M)
+48.2%
Price change (YTD)
+31.8%
Price change (1Y)
+12.9%
Trailing year
Price change (5Y)
+10.9%
52-week high
$12.78
52-week low
$5.77
Change from 52-week high
-20.6%
Change from 52-week low
+75.9%
Annualized volatility
66.3%
Annualized volatility (3M)
57.9%
Beta
1.4
RSI (14D)
43.7
Price vs SMA 50
-7.9%
Price vs SMA 200
+11.0%
Avg volume (3M)
184,576
Relative volume
0.6
Average dollar volume
$2.09M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
35.07M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
5.3×
reciprocal yield 18.8%
EV / EBITDA
—
EV / EBIT
—
P / sales
6.0×
reciprocal yield 16.6%
P / book
8.4
reciprocal yield 11.9%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-0.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
4.9×
reciprocal yield 20.4%
EV / revenue historical average (5Y)
4.9×
reciprocal yield 20.4%
EV / EBIT historical average (3Y)
46.5×
reciprocal yield 2.2%
EV / EBIT historical average (5Y)
46.5×
reciprocal yield 2.2%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-11

Profitability

9 metrics
Gross margin
—
Operating margin
-1.9%
Trailing 12 months
Net margin
-5.5%
Gross profit (TTM)
$19.99M
Operating profit (TTM)
−$1.12M
Net income (TTM)
−$3.25M
Trailing 12 months
Diluted EPS (TTM)
$-0.13
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
$0.75
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.04

Growth

11 metrics
Revenue growth YoY
+85.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$59.22M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+31.7%
Year over year · more shares
Revenue CAGR (3Y)
+207.5%
Revenue CAGR (5Y)
+194.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-7.7%
Return on assets
-4.3%
Debt / equity
0.0
Current ratio
5.8
EBITDA (TTM)
−$2.50M
Free cash flow (TTM)
—
Quick ratio
5.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$41.25M
Latest balance sheet
Cash & equivalents
$41.25M
Total assets
$75.75M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$2.04M
Capital expenditures (TTM)
$0
R&D (TTM)
$216,000
SG&A (TTM)
—
Stock compensation (TTM)
$7.50M
R&D / revenue
0.4%
Stock compensation / revenue
12.7%

Ownership (13F)

9 metrics
13F filers
106
13F filer change QoQ
+15
Institutional ownership
46.6%
Conviction holders (share of 13F filers)
3.8%
Crowding (high-turnover and private-fund holders)
22.5%
Private-fund adviser ownership
14.1%
Active holders' share change QoQ
-3.0%
Holder tenure
8.9
Price vs estimated holder cost
+42.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
7.9%

Short interest

3 metrics
Short interest
1.4%
Latest settlement · 3.8 days to cover
Days to cover
3.8d
Short-squeeze score
45 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.19M
Insider-sentiment score
43 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1211583 CUSIP 31447P100 13F (30d) 17 filings 17 filers Visit website Investor relations